Drug intelligence / Profile preview

petasites

Development stage
Unknown
Lead developer
Max Zeller Söhne
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Petasites, commonly known as butterbur, is a botanical extract derived from the roots or leaves of the *Petasites hybridus* plant. It is primarily utilized for the preventive treatment of migraine and the management of allergic rhinitis. The active constituents, petasin and isopetasin, are believed to exert therapeutic effects through the inhibition of leukotriene synthesis (via 5-lipoxygenase inhibition) and by acting as L-type calcium channel blockers, which provide anti-inflammatory and antispasmodic properties. Clinical studies, including randomized controlled trials, have demonstrated that standardized, pyrrolizidine alkaloid-free extracts (such as Petadolex) significantly reduce the frequency of migraine attacks. Due to the presence of hepatotoxic and carcinogenic pyrrolizidine alkaloids in the raw plant, commercial preparations must be processed to remove these compounds to ensure safety.

Brand names
PetadolexTesalinPetaforce
Other names
butterburPetasites hybridusPetasites extractPetasites hybridus root extract
02

Targets

ALOX5 (Arachidonate 5-lipoxygenase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)OCT3 (Organic cation transporter 3)PDE3PDE4 (Phosphodiesterase 4A1)PLA2 (Phospholipase A2 group IID)PLC (Phospholipase C family)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on petasites.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on petasites.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call